Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: A population pharmacokinetic/pharmacodynamic analysis

Yusuke Tanigawara, Kazutaka Yoshihara, Kizuku Kuramoto, Kikuo Arakawa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The objectives of this study were to identify the factors influencing antihypertensive response to the angiotensin receptor blocker, olmesartan medoxomil, or the calcium channel blocker, azelnidipine, and to discuss the possibility of utilizing them as predictors for drug selection prior to therapy. A two-way crossover study of olmesartan medoxomil and azelnidipine was conducted in 29 patients with mild to moderate essential hypertension. The 24-hour ambulatory blood pressure measurements (ABPM) and plasma drug concentrations were obtained on the first and at the end of each treatment period, and were analyzed using population pharmacokinetic/pharmacodynamic (PK/PD) modeling approach. The population PK/PD models considering circadian variations in baseline blood pressure well described the observed plasma drug concentrations and 24-hour ABPM profiles. Pre-treatment plasma renin activity (PRA) was identified as a significant covariate on the maximum drug effect (Emax) of olmesartan, whereas azelnidpine Emax was independent of patient background characteristics investigated. No patient was found to have a high Emax to one agent who also had a high Emax to the other. In conclusion, the effects of olmesartan medoxomil and azelnidipine were modestly correlated with pharmacokinetic profiles, and the pre-treatment PRA level could be a useful determinant of responsiveness in selecting olmesartan medoxomil and azelnidipine.

Original languageEnglish
Pages (from-to)376-388
Number of pages13
JournalDrug Metabolism and Pharmacokinetics
Volume24
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint

Pharmacokinetics
Hypertension
Blood Pressure
Renin
Pharmaceutical Preparations
Population
Angiotensin Receptor Antagonists
Calcium Channel Blockers
Therapeutics
Cross-Over Studies
Antihypertensive Agents
olmesartan
azelnidipine
Olmesartan Medoxomil

Keywords

  • Antihypertensive agents
  • Azelnidipine
  • Individualization
  • Olmesartan medoxomil
  • Population pharmacokinetics/pharmacodynamics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Pharmaceutical Science

Cite this

Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension : A population pharmacokinetic/pharmacodynamic analysis. / Tanigawara, Yusuke; Yoshihara, Kazutaka; Kuramoto, Kizuku; Arakawa, Kikuo.

In: Drug Metabolism and Pharmacokinetics, Vol. 24, No. 4, 2009, p. 376-388.

Research output: Contribution to journalArticle

@article{b93c9a70963b412084778c27e6c7e3c4,
title = "Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: A population pharmacokinetic/pharmacodynamic analysis",
abstract = "The objectives of this study were to identify the factors influencing antihypertensive response to the angiotensin receptor blocker, olmesartan medoxomil, or the calcium channel blocker, azelnidipine, and to discuss the possibility of utilizing them as predictors for drug selection prior to therapy. A two-way crossover study of olmesartan medoxomil and azelnidipine was conducted in 29 patients with mild to moderate essential hypertension. The 24-hour ambulatory blood pressure measurements (ABPM) and plasma drug concentrations were obtained on the first and at the end of each treatment period, and were analyzed using population pharmacokinetic/pharmacodynamic (PK/PD) modeling approach. The population PK/PD models considering circadian variations in baseline blood pressure well described the observed plasma drug concentrations and 24-hour ABPM profiles. Pre-treatment plasma renin activity (PRA) was identified as a significant covariate on the maximum drug effect (Emax) of olmesartan, whereas azelnidpine Emax was independent of patient background characteristics investigated. No patient was found to have a high Emax to one agent who also had a high Emax to the other. In conclusion, the effects of olmesartan medoxomil and azelnidipine were modestly correlated with pharmacokinetic profiles, and the pre-treatment PRA level could be a useful determinant of responsiveness in selecting olmesartan medoxomil and azelnidipine.",
keywords = "Antihypertensive agents, Azelnidipine, Individualization, Olmesartan medoxomil, Population pharmacokinetics/pharmacodynamics",
author = "Yusuke Tanigawara and Kazutaka Yoshihara and Kizuku Kuramoto and Kikuo Arakawa",
year = "2009",
doi = "10.2133/dmpk.24.376",
language = "English",
volume = "24",
pages = "376--388",
journal = "Drug Metabolism and Pharmacokinetics",
issn = "1347-4367",
publisher = "Japanese Society for the Study of Xenobiotics",
number = "4",

}

TY - JOUR

T1 - Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension

T2 - A population pharmacokinetic/pharmacodynamic analysis

AU - Tanigawara, Yusuke

AU - Yoshihara, Kazutaka

AU - Kuramoto, Kizuku

AU - Arakawa, Kikuo

PY - 2009

Y1 - 2009

N2 - The objectives of this study were to identify the factors influencing antihypertensive response to the angiotensin receptor blocker, olmesartan medoxomil, or the calcium channel blocker, azelnidipine, and to discuss the possibility of utilizing them as predictors for drug selection prior to therapy. A two-way crossover study of olmesartan medoxomil and azelnidipine was conducted in 29 patients with mild to moderate essential hypertension. The 24-hour ambulatory blood pressure measurements (ABPM) and plasma drug concentrations were obtained on the first and at the end of each treatment period, and were analyzed using population pharmacokinetic/pharmacodynamic (PK/PD) modeling approach. The population PK/PD models considering circadian variations in baseline blood pressure well described the observed plasma drug concentrations and 24-hour ABPM profiles. Pre-treatment plasma renin activity (PRA) was identified as a significant covariate on the maximum drug effect (Emax) of olmesartan, whereas azelnidpine Emax was independent of patient background characteristics investigated. No patient was found to have a high Emax to one agent who also had a high Emax to the other. In conclusion, the effects of olmesartan medoxomil and azelnidipine were modestly correlated with pharmacokinetic profiles, and the pre-treatment PRA level could be a useful determinant of responsiveness in selecting olmesartan medoxomil and azelnidipine.

AB - The objectives of this study were to identify the factors influencing antihypertensive response to the angiotensin receptor blocker, olmesartan medoxomil, or the calcium channel blocker, azelnidipine, and to discuss the possibility of utilizing them as predictors for drug selection prior to therapy. A two-way crossover study of olmesartan medoxomil and azelnidipine was conducted in 29 patients with mild to moderate essential hypertension. The 24-hour ambulatory blood pressure measurements (ABPM) and plasma drug concentrations were obtained on the first and at the end of each treatment period, and were analyzed using population pharmacokinetic/pharmacodynamic (PK/PD) modeling approach. The population PK/PD models considering circadian variations in baseline blood pressure well described the observed plasma drug concentrations and 24-hour ABPM profiles. Pre-treatment plasma renin activity (PRA) was identified as a significant covariate on the maximum drug effect (Emax) of olmesartan, whereas azelnidpine Emax was independent of patient background characteristics investigated. No patient was found to have a high Emax to one agent who also had a high Emax to the other. In conclusion, the effects of olmesartan medoxomil and azelnidipine were modestly correlated with pharmacokinetic profiles, and the pre-treatment PRA level could be a useful determinant of responsiveness in selecting olmesartan medoxomil and azelnidipine.

KW - Antihypertensive agents

KW - Azelnidipine

KW - Individualization

KW - Olmesartan medoxomil

KW - Population pharmacokinetics/pharmacodynamics

UR - http://www.scopus.com/inward/record.url?scp=70350450972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350450972&partnerID=8YFLogxK

U2 - 10.2133/dmpk.24.376

DO - 10.2133/dmpk.24.376

M3 - Article

C2 - 19745564

AN - SCOPUS:70350450972

VL - 24

SP - 376

EP - 388

JO - Drug Metabolism and Pharmacokinetics

JF - Drug Metabolism and Pharmacokinetics

SN - 1347-4367

IS - 4

ER -